

1 **Associations of salivary cortisol with cardiovascular parameters and mortality in**
2 **the MRC National Survey of Health and Development (NSHD)**

3 **Authors**

4 Lamia Al Saikhan¹, Dylan M Williams¹, Gaby Captur¹, Alun D Hughes¹, Daniel Davis¹, Nish
5 Chaturvedi¹

6 ¹ MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK

7

8 Corresponding author: Professor Nishi Chaturvedi, Director MRC Lifelong Health and Ageing

9 Unit at UCL, University College London, 5th floor, 1-19 Torrington Place, London, WC1E

10 7HB; n.chaturvedi@ucl.ac.uk

11

12 **Abstract**

13 *Objectives*

14 Hypothalamic-pituitary-adrenal (HPA) dysregulation is a postulated risk factor for
15 cardiovascular disease but results from previous studies have been mixed. We examined
16 cross-sectional associations of diurnal patterns of salivary cortisol with 10 subclinical
17 measures of cardiovascular disease (including pulse wave velocity, carotid intima-media
18 thickness, and measures of heart structure and function), and prospective associations of
19 cortisol variation with cardiovascular (CV) and non-cardiovascular (NCV) mortality.

20 *Methods*

21 We included up to 1,263 participants of the MRC National Survey for Health and
22 Development birth cohort, who had participated in serial diurnal salivary cortisol sampling in
23 2006-2010 (aged 60–64 years). We used multivariable linear and multinomial logistic
24 regression to estimate associations of cortisol awakening response (CAR), slope and area
25 under the curve (AUC) with subclinical cardiovascular measures, and multivariable Cox
26 regression to estimate associations of the three cortisol metrics with all-cause, CV and NCV
27 mortality.

28 *Results*

29 All associations with subclinical cardiovascular measures were weak and most were
30 compatible with the null hypothesis. Each standard deviation (SD) higher cortisol AUC was
31 associated with a 1.9% (95%-CI 0.3-3.5) higher pulse wave velocity. A shallow cortisol slope
32 (per SD gradient) was associated with a 1.4% lower intima media thickness (95%-CI -2.6, -
33 0.2), and lower odds of concentric remodelling (OR 0.83, 95%-CI 0.70-0.99). Given the
34 multiple analyses performed, these could be chance findings. AUC, cortisol slope and CAR
35 were not convincingly associated with cardiovascular or total mortality, although the 95%
36 confidence intervals of hazard ratio estimates were wide.

37 *Conclusions*

38 This study provides little evidence for clinically important associations of salivary cortisol and
39 subclinical cardiovascular measures and mortality.

40 **Keywords**

41 Salivary cortisol; Cortisol Awakening response; Cortisol diurnal pattern; Atherosclerosis;

42 Mortality; Cardiovascular disease

43

44 **Article**

45 **1. Introduction**

46 The hypothalamic-pituitary-adrenal (HPA) axis controls the secretion of cortisol in response
47 to acute stressors and diurnal patterning. HPA axis dysregulation is usually characterised by
48 a blunted cortisol awakening response (CAR, the rapid increase of cortisol after waking),¹⁻³
49 higher overall cortisol secretion and a shallower decline throughout the day.^{1,4} Based on
50 animal and some human research, it has been suggested that repeated and prolonged
51 exposure to stressors across the lifetime is likely to contribute to HPA dysregulation,⁵
52 implicating the HPA axis in the pathway between psychosocial stress and health.^{6,7}

53 Several studies have suggested a link between diurnal salivary cortisol and cardiovascular
54 mortality, but results have been mixed in terms of which measures of diurnal rhythm showed
55 associations and might have been influenced by limited number of events or short follow-up.
56 ^{6,8,9} Studying subclinical measures as surrogates for clinical endpoints can improve statistical
57 power and reduce selection bias, and may help to elucidate mechanistic actions of
58 exposures. However, available evidence on associations of salivary cortisol excursions and
59 subclinical cardiovascular measures to date is inconclusive and has been limited to
60 measures of atherosclerosis.¹⁰⁻¹⁵

61 In this study we aimed to: (1) investigate the cross-sectional associations of diurnal patterns
62 of salivary cortisol with multiple subclinical measures of cardiovascular disease; (2)
63 investigate the prospective associations of diurnal salivary cortisol patterns with
64 cardiovascular and non-cardiovascular mortality in participants of the MRC National Survey
65 for Health and Development study (NSHD), aged 60-64 years at cortisol sampling. We
66 hypothesised that HPA axis dysregulation would be associated with evidence of subclinical
67 cardiovascular disease and cardiovascular mortality.

68 **2. Materials and methods**

69 *2.1. Study Population*

70 We analysed data from participants from the NSHD, a birth cohort of 5362 individuals born
71 Britain in one week of March 1946. At age 60-64 years (2006-2010), participants were
72 invited to a clinic assessment that included health, lifestyle and socio-demographic
73 questionnaires, cardiovascular measures and a serial salivary cortisol collection protocol.
74 Ethical approval for the study was obtained from various regional ethics committees, and
75 participants provided written informed consent for each component of data collection.¹⁶

76 *2. Assessment of diurnal salivary cortisol*

77 Participants provided four saliva samples over 24 hours: i) during their clinic appointment, ii)
78 the same day between 21:00 – 21:30, iii) on waking the following day, and iv) 30 minutes
79 later. At the clinic, a research nurse explained the protocol for home cortisol collection,
80 including requests not to eat, drink or smoke for 30 minutes before each sample collection,
81 and to report any protocol deviations.¹⁷ Salivettes were returned via post and frozen before
82 radioimmunoassay in Dresden, Germany.³ Cortisol collection was not conducted for a
83 subset of participants attending a clinic in Manchester (n=348) because these were part of a
84 previous feasibility sample that did not include cortisol sampling.

85 We used the four data cortisol points to calculate three diurnal cortisol measures: (1) cortisol
86 awakening response (CAR), which is regulated separately from the diurnal cycle.¹⁸ This was
87 measured as the difference between the waking cortisol and the sample 30 minutes later;
88 (2) Diurnal cortisol slope, derived from a random-effects linear regression of the log-
89 transformed cortisol across the first, third and fourth cortisol measurements resulting in a
90 negative slope variable with steeper slopes represented by more negative values;⁶ (3) Area
91 under the curve (AUC), using mean time between measurements, to quantify overall cortisol
92 exposure.^{2,19}

93 *2.3. Outcome assessment*

94 Subclinical cardiovascular measures included carotid-femoral pulse wave velocity (PWV),
95 common carotid artery intima-media thickness (cIMT), and measures of cardiac structure
96 (left ventricular (LV) mass indexed for height,^{2,7} left atrial (LA) volume indexed for body
97 surface area (BSA), LV relative wall thickness (RWT), and LV remodelling categories (Lang
98 et al. 2015) , and function (ejection fraction (EF), peak early systolic velocity of the mitral
99 annulus (s'), peak early diastolic mitral annulus velocity (e'), ratio of peak early diastolic
100 mitral inflow velocity to peak early diastolic mitral annulus velocity (E/e'), N-terminal-pro B-
101 type natriuretic peptide (NT-proBNP), a global measure of LV function and independent
102 biomarker for heart failure prognosis.²⁰ Cardiac structure and function were measured with
103 echocardiography using a GE Vivid-I ultrasound scanner. Images were recorded from
104 parasternal long axis and short axis views, apical 5-chamber, 4-chamber, 3-chamber, 2-
105 chamber and aortic views (as well as a tissue Doppler in 4-chamber view).¹⁶ The following
106 cardiac structure parameters were calculated according to recommendations by the
107 American Society of Echocardiography: LV mass indexed for height,^{2,7} relative wall
108 thickness, remodelling categories (normal defined as $RWT \leq 0.42$ and LV mass indexed for
109 BSA of $\leq 95 \text{ gm/m}^2$ for women and ≤ 115 for men, eccentric hypertrophy defined as RWT
110 ≤ 0.42 and LV mass indexed for BSA > 95 for women and > 115 for men, concentric
111 remodelling defined as $RWT > 0.42$ and LV mass indexed for BSA of ≤ 95 for women and
112 ≤ 115 for men, and concentric hypertrophy defined as $RWT > 0.42$ and LV mass indexed for
113 BSA of > 95 or women and > 115 for men),²¹ the systolic function parameters EF, s', and the
114 diastolic function parameters LA volume indexed to body surface area and E/e'.^{21,22} NT-
115 proBNP was measured using automated electrochemiluminescence immunoassay (R&D
116 Systems Abingdon, UK).²³ PWV was measured using a Vicorder device.²⁴ PWV above
117 30m/s were capped. cIMT was measured bilaterally using a GE Vivid-I ultrasound scanner
118 and calculated using automated software.²⁵

119 Mortality information was available through linked death records until December 31, 2021, a
120 mean 12 years from cortisol data collection. Cardiovascular death was defined as the
121 primary cause coded by International Classification of Disease 10 as I100I199 and 9 401–
122 454; non-cardiovascular death was defined as any other cause of death. Deaths from
123 unknown cause were excluded from non-cardiovascular death.

124 *2.4. Confounders*

125 Noise variables and potential confounders were selected based on recommendations for
126 salivary cortisol analyses and expected associations with cardiovascular outcomes,
127 respectively: waking time, having eaten or drunk before cortisol measurement, leisure time
128 physical activity and education.² We also investigated potential mediation by BMI and overall
129 cardiovascular risk. BMI was measured by trained staff using a standardised protocol;
130 education and leisure time physical activity were self-reported. Cardiovascular risk was
131 quantified by calculation of a Framingham risk score using age, sex, measured HDL and
132 LDL cholesterol, systolic and diastolic blood pressure, diabetes (based on self-report and/or
133 use of antidiabetic drugs or insulin) and smoking).²⁶

134 **3. Statistical analysis**

135 Participants were excluded from analyses if they had not participated in the saliva sample
136 collection at all four time points, took steroid medications, smoked within 30 minutes of
137 cortisol measurement, missed recording the measurement time, were probably shift-working
138 (waking before 4.00 or after 12.00), took the evening measurement before 20:00, collected
139 samples in the wrong order and if the 30-minute post-waking measurement was done >1h
140 after waking.¹⁷ Continuous outcome measures were log-transformed to account for skewed
141 distributions in most measures. We undertook complete-case analyses for those with cortisol
142 data and confounder data (variables included in model 1-3, below) since missingness among
143 confounders was less than 6%.

144 We used multivariable linear regression to estimate the association of CAR, slope and AUC
145 with each cardiovascular structural and functional measure (except where remodelling
146 category was the outcome; here, we used multinomial logistic regression) and Cox
147 regression to estimate hazard ratios (HR) for all-cause mortality, cardiovascular and non-
148 cardiovascular mortality. CAR, slope and AUC were entered in models as continuous
149 variables with units representing per standard deviation (SD) increase. We tested for non-
150 linearity between exposures and outcomes using fractional polynomial models. We
151 multiplied β -coefficients by 100 to yield percentage differences in outcomes per SDs of
152 exposure.²⁷ We used four sequential models to assess the effects on estimates of adjusting
153 for potential confounders and noise variables (models 1 and 2) and covariates that could lie
154 on the pathway between exposure and outcome (models 3 and 4). Model 1 was adjusted for
155 sex, waking time (per hour later), eating or drinking before cortisol measurement (yes/no).
156 Model 2 additionally adjusted for education (no qualification/ vocational only/ O level or
157 equivalent/ A level or equivalent/ higher education) and leisure time physical activity (none/
158 1-4 times per week/ ≥ 5 times per week); Model 3 was additionally adjusted for BMI and
159 Model 4 for Framingham risk score.

160 Based on earlier findings reporting sex differences in the association of cortisol slope and
161 PWV,¹⁴ we compared models with and without an interaction term by sex using likelihood-
162 ratio tests. We conducted three sensitivity analyses: (1) excluding log cortisol and
163 cardiovascular parameters beyond ± 3 SD of mean values to identify the impact of outliers;
164 (2) excluding participants with self-reported clinical diagnoses of myocardial infarction and
165 angina since 1999 (cases $n=70$) to rule out any role for overt coronary heart disease; (3)
166 excluding any deaths within the two years of follow-up which may mitigate bias from reverse
167 causality.

168 We did not formally appraise results with a threshold of statistical significance adjusted for a
169 burden of multiple testing, but interpreted any unclear associations cautiously in light of the
170 many exposure-outcome associations tested in these analyses.

171 **4. Results**

172 1,669 participants provided saliva samples at all four time points, of which 330 had to be
173 excluded and an additional 78 had missing confounder data – leaving an analytical sample
174 of 1,263 (Table 1). Based on outcome availability, sample sizes ranged from 867 for EF to
175 1169 for NT-proBNP. There was little difference in heart and vascular measures when
176 comparing included participants to ineligible participants from the wider cohort (Table 1), but
177 those excluded had lower education levels, were more likely to be men and had higher
178 Framingham risk scores (Supplementary Table S1).

179 There was no convincing association between cortisol awakening response and any
180 cardiovascular parameter (Table 2). A shallow (i.e. less negative) cortisol slope was
181 associated with a 1.4% lower cIMT (95%-CI -2.6, -0.2; Table 2), and a lower odds of
182 concentric remodelling (OR 0.83, 95%-CI 0.70, 0.99; Table 3) in models adjusted for sex,
183 any eating or drinking, waking time, education, and physical activity. Each standard deviation
184 higher cortisol AUC was associated with a 1.9% (95%-CI 0.3, 3.5) higher pulse wave velocity
185 and a 1.5% (95%-CI 0.0, 2.9) higher s' . These associations did not differ substantially when
186 fewer covariates were included (supplementary Table S2) and mostly remained when
187 additionally adjusted for BMI and Framingham risk scores. The association of AUC and s'
188 was attenuated with additional adjustment for Framingham risk scores. There was no
189 association between cortisol slope and AUC with any other vascular and cardiac parameter.
190 Associations showed no evidence for non-linearity (P values >0.07) or modification by sex (P
191 values for interaction >0.05), except CAR and EF (P value for sex interaction=0.03, adjusted
192 % difference in men -1.2, 95%-CI -2.5, 0.2; in women 0.8, 95%-CI -0.5, 2.1).

193 In sensitivity analyses excluding potential outliers, there was an additional inverse
194 association of AUC and cIMT (-1.2%, 95%-CI -2.3, -0.1) and AUC was not associated with
195 s' , suggesting these associations were driven by outliers. In sensitivity analyses excluding
196 people with prevalent myocardial infarction and angina, there was an additional inverse

197 association of CAR and PWV (-1.90%, 95%-CI -3.75, -0.05), and all other associations from
198 the main analyses were similar (Supplementary Table S4).

199 Linked data were available for 1069 participants. Over a mean 12 years of follow-up there
200 were 104 total deaths, 23 cardiovascular and 76 non-cardiovascular deaths. There were no
201 clear associations between CAR, cortisol slope, and AUC with all-cause, cardiovascular and
202 non-cardiovascular mortality in models adjusted for sex, any eating or drinking, waking time,
203 education, and physical activity (Figure 1). However, we note that the precision of these
204 estimates was limited due to few disease events in the sample. Associations of AUC with
205 outcomes showed an inverse direction. Results did not substantially differ when fewer
206 covariates were included and after additional adjustment for BMI and Framingham risk
207 score, and showed no evidence for non-linearity (P value >0.09) and sex differences (P
208 value >0.2). In sensitivity analyses, the overall results for the association of cortisol
209 measures and mortality did not differ (Supplementary Table S5).

210 **5. Discussion**

211 In this study of older British adults, there was little evidence that variation in diurnal cortisol
212 was associated with subclinical cardiovascular disease or incidence cardiovascular
213 mortality. The observed positive associations of average daily cortisol (AUC) with arterial
214 stiffness, and lower cIMT, and shallow cortisol slope with lower cIMT and lower likelihood of
215 concentric remodelling, were very weak.

216 Our findings add to current knowledge on the relationship between cortisol and
217 atherosclerosis or arterial stiffness (arteriosclerosis). Two studies of participants around the
218 ages of 40 (sample sizes 718 and 488) had previously found an association between a
219 flatter cortisol slope and higher cIMT and risk of coronary artery calcification (CAC).^{11,15} A
220 study in 1866 older participants (mean 75 years) found AUC to be associated with a higher
221 plaque score.¹⁰ However, a study of 610 participants in the Multi-Ethnic Study of
222 Atherosclerosis of similar age to our study found weak and directionally inconsistent

223 associations between cortisol and two subclinical measure of atherosclerosis (CAC and
224 brachial ankle index),¹² and a study of 367 women in the Coronary Artery Risk
225 Development in Young Adults study found no association between AUC or slope and CAC
226 or cIMT.¹³ Apart from Dekker *et al.*,¹⁰ no other study found an association of CAR and AUC
227 with measures of subclinical atherosclerosis.^{11-13,15} A longitudinal study of 3281 participants
228 of ~65 years of age found no associations between salivary cortisol and PWV but observed
229 that a more shallow salivary cortisol slope at baseline was associated with a greater change
230 in PWV over the subsequent 5 years in women but not in men.¹⁴ Hajat *et al.* hypothesised
231 that cortisol might be more relevant in the development of atherosclerosis at younger ages
232 and of lesser importance in older age.¹² However, this view is not be supported by a
233 Mendelian randomisation study which used genetic variants to index long-term exposure to
234 circulating cortisol, and found no evidence for effects of cortisol exposure on
235 cardiometabolic diseases.²⁸ We also note that previous studies on cortisol and CVD
236 measures to have reported associations in line with the hypothesis of the role of HPA
237 dysregulation on CVD outcomes were often limited to few subclinical measures or showed
238 associations with only few measures of cortisol pattern and some results being limited to
239 subgroups.^{6,8,10-15} Another consideration is that the evidence might be affected by
240 publication bias with unexpected or null findings not yielding peer-reviewed publications.

241 To the best of our knowledge, this is the first study to report the association of salivary
242 cortisol and heart function and structure. We found little or no convincing evidence of
243 relationships: a weak positive association with s' was driven by outliers, and an association
244 of a more shallow slope with lower odds of concentric remodelling was unexpected and
245 inconsistent with associations with PWV. Concentric remodelling can occur in response to
246 chronic pressure, overload or MI.²⁹ However, we cannot rule out that this was a chance
247 finding due to multiple testing and potentially exacerbated by reduced power due to
248 multinomial analyses requiring large sample sizes.

249 We found no evidence of an association of diurnal cortisol measures with CV or non-CV
250 mortality. However, estimates were imprecise and we cannot exclude the possibility of
251 clinically important associations. A recent study of 1090 participants of a representative
252 German sample (mean age 60) including 87 deaths (of which 31 were cardiovascular) had
253 found no suggestion of an association with AUC.⁸ Across all cortisol measures, previous
254 evidence is mixed. The aforementioned study found an inverse association of CAR, and
255 peak-to-bedtime ratio, reflecting a steeper slope and lower risk of CVD deaths and a study of
256 4047 participants of the Whitehall II study, with 139 total and 32 CV deaths, showed a more
257 shallow salivary cortisol slope to be associated with greater CVD mortality risk⁶. However, a
258 study of older adults (mean 76 years) including 85 fatal CHD cases found no association
259 with cortisol slope.⁹

260 Strengths of the study were the long follow-up (12 years) for analyses of mortality and the
261 use of a large array of detailed subclinical cardiovascular measures. The availability of
262 several salivary cortisol measures across the day allowed us to investigate diurnal cortisol
263 rhythm including CAR, diurnal cortisol slope as well as the average level across the day.² e
264 also emphasise several limitations. First, we cannot exclude the possibility that associations
265 found might have occurred by chance (false positives), especially considering multiple
266 testing in relation to the large number of exposure-outcome analyses. Conversely, precision
267 for detecting associations was clearly limited in some circumstances – notably the analyses
268 of incident mortality risk (raising the possibility of false negative findings). Cortisol was only
269 measured on four occasions over 24 hours which could introduce measurement error that
270 would bias results towards the null, especially for models involving AUC. Cortisol
271 measurements have large day-to-day variations,³⁰ and may be influenced by emotional
272 experiences on the day, or preceding day of measurement.³¹ A study comparing the
273 estimation of cortisol slope, CAR and AUC using fewer than an hourly measurement protocol
274 suggested that slope and CAR can be estimated from as little as two measurements without
275 loss of information, but that AUC estimations of fewer than hourly measurements were less

276 well correlated.³² Another consideration is that these analyses are observational and results
277 might have been affected by residual confounding and reverse causation. The findings might
278 also have been affected by selection biases: it is possible that participants with more HPA
279 dysregulation were more likely to be missing from the sample, and there might also be
280 competing risks affecting mortality associations. Finally, generalisability might be limited by
281 the study sample which is exclusively of European ethnicity and shows a healthy cohort
282 effect with more advantaged participants having remained in follow-up over the decades of
283 the study, and given that these participants are all of a single age, there may also be secular
284 differences in these associations in other generations.

285 *Future directions*

286 In conclusion, this study does not provide convincing evidence for a clinically important link
287 between HPA dysregulation and subclinical cardiovascular disease or cardiovascular
288 mortality. However, future studies using a broad array of cardiovascular measures, as well
289 as a larger burden of incident disease could address the current limitations of the evidence
290 base to further characterise the relative importance of the cortisol pathway for CVD.

291

292 *Funding*

293 The MRC Unit for Lifelong Health and Ageing at UCL is funded by the Medical Research
294 Council (MC_UU_00019/2).

295

296 *Acknowledgements*

297 We would like to thank the NSHD participants and the numerous team members involved in
298 the study including interviewers, technicians, researchers, administrators, managers, health
299 professionals and volunteers. We are additionally grateful to our funders for their financial
300 input and support in making this research happen.

301 *Data availability*

It is made available under a [CC-BY 4.0 International license](#) .

302 Data used in this publication are available to bona fide researchers upon request to the
303 NSHD Data Sharing Committee via a standard application procedure. Further details can be
304 found at <http://www.nshd.mrc.ac.uk/data>

References

1. Gaffey AE, Bergeman CS, Clark LA, Wirth MM. Aging and the HPA axis: Stress and resilience in older adults. *Neuroscience & Biobehavioral Reviews*. 2016/09/01/ 2016;68:928-945. doi:<https://doi.org/10.1016/j.neubiorev.2016.05.036>
2. Adam EK, Kumari M. Assessing salivary cortisol in large-scale, epidemiological research. *Psychoneuroendocrinology*. 2009/11/01/ 2009;34(10):1423-1436. doi:<https://doi.org/10.1016/j.psyneuen.2009.06.011>
3. Kirschbaum C, Hellhammer DH. Salivary Cortisol in Psychobiological Research: An Overview. *Neuropsychobiology*. 1989;22(3):150-169. doi:10.1159/000118611
4. Fries E, Dettenborn L, Kirschbaum C. The cortisol awakening response (CAR): Facts and future directions. *International Journal of Psychophysiology*. 2009/04/01/ 2009;72(1):67-73. doi:<https://doi.org/10.1016/j.ijpsycho.2008.03.014>
5. Flier JSMD, Underhill LH, McEwen BSP. Protective and damaging effects of stress mediators. *The New England Journal of Medicine*. 1998 Jan 15 1998;338(3):171-179.
6. Kumari M, Shipley M, Stafford M, Kivimäki M. Association of diurnal patterns in salivary cortisol with all-cause and cardiovascular mortality: findings from the Whitehall II study. *J Clin Endocrinol Metab*. May 2011;96(5):1478-85. doi:10.1210/jc.2010-2137
7. Steptoe A, Kivimäki M. Stress and cardiovascular disease. *Nature Reviews Cardiology*. 2012/06/01 2012;9(6):360-370. doi:10.1038/nrcardio.2012.45
8. Karl S, Johar H, Ladwig K-H, Peters A, Lederbogen F. Dysregulated diurnal cortisol patterns are associated with cardiovascular mortality: Findings from the

KORA-F3 study. *Psychoneuroendocrinology*. 2022/07/01/ 2022;141:105753.

doi:<https://doi.org/10.1016/j.psyneuen.2022.105753>

9. Groffen DA, Bosma H, Koster A, et al. A blunted diurnal cortisol response in the lower educated does not explain educational differences in coronary heart disease: findings from the AGES-Reykjavik study. *Soc Sci Med*. Feb 2015;127:143-

9. doi:10.1016/j.socscimed.2014.09.050

10. Dekker MJ, Koper JW, van Aken MO, et al. Salivary cortisol is related to atherosclerosis of carotid arteries. *J Clin Endocrinol Metab*. Oct 2008;93(10):3741-7.

doi:10.1210/jc.2008-0496

11. Matthews K, Schwartz J, Cohen S, Seeman T. Diurnal cortisol decline is related to coronary calcification: CARDIA study. *Psychosom Med*. Sep-Oct

2006;68(5):657-61. doi:10.1097/01.psy.0000244071.42939.0e

12. Hajat A, Diez-Roux AV, Sánchez BN, et al. Examining the association between salivary cortisol levels and subclinical measures of atherosclerosis: The

Multi-Ethnic Study of Atherosclerosis. *Psychoneuroendocrinology*. 2013/07/01/

2013;38(7):1036-1046. doi:<https://doi.org/10.1016/j.psyneuen.2012.10.007>

13. Lee J-M, Colangelo LA, Schwartz JE, et al. Associations of cortisol/testosterone and cortisol/sex hormone-binding globulin ratios with atherosclerosis in middle-age women. *Atherosclerosis*. 2016/05/01/ 2016;248:203-

209. doi:<https://doi.org/10.1016/j.atherosclerosis.2016.03.028>

14. Ikeda A, Steptoe A, Shipley M, et al. Diurnal pattern of salivary cortisol and progression of aortic stiffness: Longitudinal study. *Psychoneuroendocrinology*. Nov

2021;133:105372. doi:10.1016/j.psyneuen.2021.105372

15. Miller KG, Gianaros PJ, Kamarck TW, Anderson BA, Muldoon MF, Manuck SB. Cortisol activity partially accounts for a relationship between community

socioeconomic position and atherosclerosis. *Psychoneuroendocrinology*.

2021/09/01/ 2021;131:105292. doi:<https://doi.org/10.1016/j.psyneuen.2021.105292>

16. Kuh D, Pierce M, Adams J, et al. Cohort Profile: Updating the cohort profile for the MRC National Survey of Health and Development: a new clinic-based data collection for ageing research. *International Journal of Epidemiology*. 2011;40(1):e1-e9. doi:10.1093/ije/dyq231

17. Stafford M, Gardner M, Kumari M, Kuh D, Ben-Shlomo Y. Social isolation and diurnal cortisol patterns in an ageing cohort. *Psychoneuroendocrinology*. 2013/11/01/ 2013;38(11):2737-2745. doi:<https://doi.org/10.1016/j.psyneuen.2013.07.002>

18. Steptoe A, Serwinski B. Cortisol awakening response. *Stress: Concepts, cognition, emotion, and behavior*. Elsevier Academic Press; 2016:277-283. *Handbook of stress*.

19. Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. *Psychoneuroendocrinology*. Oct 2003;28(7):916-31. doi:10.1016/s0306-4530(02)00108-7

20. Chow SL, Maisel AS, Anand I, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. *Circulation*. 2017/05/30 2017;135(22):e1054-e1091. doi:10.1161/CIR.0000000000000490

21. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Journal of the American Society of Echocardiography*. 2015/01/01/ 2015;28(1):1-39.e14. doi:<https://doi.org/10.1016/j.echo.2014.10.003>

22. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Journal of the American Society of Echocardiography*. 2016/04/01/ 2016;29(4):277-314. doi:<https://doi.org/10.1016/j.echo.2016.01.011>
23. Kuh D, Cooper R, Sattar N, Welsh P, Hardy R, Ben-Shlomo Y. Systemic Inflammation and Cardio-Renal Organ Damage Biomarkers in Middle Age Are Associated With Physical Capability Up to 9 Years Later. *Circulation*. 2019/04/23 2019;139(17):1988-1999. doi:10.1161/CIRCULATIONAHA.118.037332
24. Masi S, Georgiopoulos G, Khan T, et al. Patterns of adiposity, vascular phenotypes and cognitive function in the 1946 British Birth Cohort. *BMC Medicine*. 2018/05/28 2018;16(1):75. doi:10.1186/s12916-018-1059-x
25. Charakida M, Khan T, Johnson W, et al. Lifelong patterns of BMI and cardiovascular phenotype in individuals aged 60–64 years in the 1946 British birth cohort study: an epidemiological study. *The Lancet Diabetes & Endocrinology*. 2014;2(8):648-654. doi:10.1016/S2213-8587(14)70103-2
26. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of Coronary Heart Disease Using Risk Factor Categories. *Circulation*. 1998/05/12 1998;97(18):1837-1847. doi:10.1161/01.CIR.97.18.1837
27. Cole TJ, Altman DG. Statistics Notes: Percentage differences, symmetry, and natural logarithms. *BMJ*. 2017;358:j3683. doi:10.1136/bmj.j3683
28. Kwok MK, Kawachi I, Rehkopf D, Schooling CM. The role of cortisol in ischemic heart disease, ischemic stroke, type 2 diabetes, and cardiovascular disease risk factors: a bi-directional Mendelian randomization study. *BMC medicine*. 2020;18:1-14.

29. Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)†. *Eur Heart J Cardiovasc Imaging*. Jun 2015;16(6):577-605.

doi:10.1093/ehjci/jev076

30. Ross KM, Murphy ML, Adam EK, Chen E, Miller GE. How stable are diurnal cortisol activity indices in healthy individuals? Evidence from three multi-wave studies. *Psychoneuroendocrinology*. 2014;39:184-193.

31. Adam EK, Hawkley LC, Kudielka BM, Cacioppo JT. Day-to-day dynamics of experience–cortisol associations in a population-based sample of older adults. *Proceedings of the National Academy of Sciences*. 2006/11/07 2006;103(45):17058-17063. doi:10.1073/pnas.0605053103

32. Hoyt LT, Ehrlich KB, Cham H, Adam EK. Balancing scientific accuracy and participant burden: testing the impact of sampling intensity on diurnal cortisol indices. *Stress*. 2016/09/02 2016;19(5):476-485. doi:10.1080/10253890.2016.1206884

Table 1: Characteristics for total sample and by sex

Characteristic	Total sample		Men		Women	
	n (%) / mean		n (%) / mean		n (%) / mean	
	N	(SD)	N	(SD)	N	(SD)
CAR nmol	1,263	6.05 (12.06)	590	4.75 (12.46)	673	7.19 (11.58)
Cortisol slope nmol/h	1,263	-0.13 (0.01)	590	-0.13 (0.01)	673	-0.13 (0.01)
Daytime cortisol AUC						
nmol/h	1,263	10.21 (4.77)	590	10.71 (5.06)	673	9.78 (4.46)
PWV, distance/time						
(m/s)	880	8.35 (2.68)	409	8.37 (2.34)	471	8.33 (2.95)
clMT (mm)	749	0.69 (0.12)	347	0.71 (0.13)	402	0.67 (0.11)
LV mass indexed for						
height ^{2.7} (g/m ^{2.7})	876	44.32 (13.80)	405	46.70 (14.84)	471	42.27 (12.49)
RWT	876	0.42 (0.10)	405	0.42 (0.09)	471	0.41 (0.11)
EF (%)	867	64.29 (7.95)	423	63.47 (7.92)	444	65.08 (7.91)
s' (cm/s)	880	7.79 (1.61)	407	8.07 (1.71)	473	7.55 (1.49)
LA volume indexed to						
BSA (ml/m ²)	831	23.47 (8.17)	406	24.56 (8.80)	425	22.43 (7.38)
E/e', %	907	7.92 (2.16)	424	7.54 (2.15)	483	8.25 (2.12)
		91.82				
NT-proBNP (pg/ml)	1,169	(168.84)	559	95.14 (208.27)	610	88.77 (122.11)
Remodelling	876		405		471	
normal		380 (43.4)		170 (42.0)		210 (44.6)
concentric						
hypertrophy		143 (16.3)		65 (16.1)		78 (16.6)
eccentric						
hypertrophy		128 (14.6)		58 (14.3)		70 (14.9)

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

concentric						
remodelling		225 (25.7)		112 (27.7)		113 (24.0)
Any eating/drinking						
prior to cortisol						
measurement	1,263		590		673	
no		1,074 (85.0)		493 (83.6)		581 (86.3)
yes		189 (15.0)		97 (16.4)		92 (13.7)
Waking time	1,263		590		673	
before 6am		144 (11.4)		76 (12.9)		68 (10.1)
6-6.30am		172 (13.6)		91 (15.4)		81 (12.0)
6.30-7am		243 (19.2)		125 (21.2)		118 (17.5)
7-7.30am		257 (20.4)		113 (19.2)		144 (21.4)
7.30-8am		197 (15.6)		76 (12.9)		121 (18.0)
8-8.30am		132 (10.5)		63 (10.7)		69 (10.3)
after 8.30am		118 (9.3)		46 (7.8)		72 (10.7)
Highest educational						
attainment	1,263		590		673	
<O level/equivalent		419 (33.2)		188 (31.9)		231 (34.3)
O level/equivalent		248 (19.6)		74 (12.5)		174 (25.9)
≥A level/equivalent		596 (47.2)		328 (55.6)		268 (39.8)
Leisure time physical						
activity	1,263		590		673	
none		784 (62.1)		368 (62.4)		416 (61.8)
1-4times/week		188 (14.9)		89 (15.1)		99 (14.7)
5+times/week		291 (23.0)		133 (22.5)		158 (23.5)
Framingham Risk						
Score	1,049	6.83 (2.47)	505	5.98 (1.95)	544	7.62 (2.64)

BMI kg/m² 1,260 27.88 (4.95) 588 27.97 (4.05) 672 27.80 (5.62)

Abbreviations: AUC, area under the curve from the ground; BMI, body mass index; BSA, body surface area; CAR, cortisol awakening response; cIMT, carotid intima-media thickness; E/e', early diastolic mitral inflow velocity to early diastolic mitral annulus velocity ratio; EF, Biplane Ejection fraction; LA, left atrium; LV, left ventricular; NT-proBNP, N-terminal-pro B-type natriuretic peptide; PWV, pulse wave velocity; RWT, relative wall thickness; S', Systolic wave prime.

Table 2: Adjusted associations of cortisol measures (per SD) and cardiovascular parameters

Cortisol measure (interpretation)	Cardiovascular parameter	Interpretation	N	% difference (95% CI)		
				per SD	P value	P for sex interaction
	<i>Vascular health</i>					
	PWV	↑ worse	880	-1.56 (-3.15, 0.04)	0.06	0.74
	cIMT	↑ worse	903	-0.09 (-1.26, 1.08)	0.88	0.51
	<i>Cardiac structure</i>					
	LV mass/height ^{2.7}	↑ worse	876	-0.16 (-2.04, 1.72)	0.87	0.36
	RWT	↑ worse	876	0.08 (-0.57, 0.73)	0.80	0.44
	<i>Cardiac systolic function</i>					
CAR (↑better)	EF	↑better	867	-0.28 (-1.20, 0.65)	0.56	0.03
	S'	↑better	880	-0.04 (-1.39, 1.32)	0.96	0.97
	<i>Cardiac diastolic function</i>					
	LA volume/BSA	↑ worse	831	0.51 (-1.77, 2.78)	0.66	0.60
	E/e'	↑ worse	907	0.15 (-1.54, 1.85)	0.86	0.73
	<i>Biomarker</i>					
	NT-proBNP	↑ worse	1169	-1.25 (-6.77, 4.28)	0.66	0.88

	<i>Vascular health</i>					
	PWV	↑ worse	880	0.92 (-0.73, 2.58)	0.27	0.59
	cIMT	↑ worse	903	-1.41 (-2.58, -0.23)	0.02	0.98
	<i>Cardiac structure</i>					
	LV mass/height ^{2.7}	↑ worse	876	0.17 (-1.78, 2.12)	0.87	0.05
	RWT	↑ worse	876	-0.40 (-1.08, 0.27)	0.24	0.25
	<i>Cardiac systolic function</i>					
Slope (↑ worse)	EF	↑ better	867	-0.12 (-1.08, 0.83)	0.80	0.14
	s'	↑ better	880	1.29 (-0.11, 2.70)	0.07	0.38
	<i>Cardiac diastolic function</i>					
	LA volume/BSA	↑ worse	831	0.10 (-2.31, 2.52)	0.93	0.49
	E/e'	↑ worse	907	1.18 (-0.59, 2.95)	0.19	0.09
	<i>Biomarker</i>					
	NT-proBNP	↑ worse	1169	0.10 (-5.60, 5.79)	0.97	0.11
	<i>Vascular health</i>					
AUC (↑ worse)	PWV	↑ worse	880	1.93 (0.34, 3.52)	0.02	0.13
	cIMT	↑ worse	903	-1.06 (-2.21, 0.09)	0.07	0.79

<i>Cardiac structure</i>						
LV mass/height ^{2.7}	↑ worse	876	-0.16 (-2.07, 1.76)	0.87		0.23
RWT	↑ worse	876	-0.16 (-0.82, 0.50)	0.63		>0.99
<i>Cardiac systolic function</i>						
EF	↑ better	867	-0.23 (-1.16, 0.69)	0.62		0.12
S'	↑ better	880	1.47 (0.03, 2.91)	0.05		0.16
<i>Cardiac diastolic function</i>						
LA volume/BSA	↑ worse	831	0.86 (-1.44, 3.16)	0.46		0.84
E/e'	↑ worse	907	-0.19 (-1.93, 1.55)	0.83		0.57
<i>Biomarker</i>						
NT-proBNP	↑ worse	1169	2.22 (-3.49, 7.92)	0.45		0.62

Associations adjusted for sex, waking time, eating or drinking prior to cortisol measurement, education and leisure time physical activity.

Abbreviations: AUC, area under the curve from the ground; BMI, body mass index; BSA, body surface area; CAR, cortisol awakening response; cIMT, carotid intima-media thickness; E/e', early diastolic mitral inflow velocity to early diastolic mitral annulus velocity ratio; EF, Ejection fraction; LA, left atrium; LV, left ventricular; NT-proBNP, N-terminal-pro B-type natriuretic peptide; PWV, pulse wave velocity; RWT, relative wall thickness; S', Systolic wave prime.

Table 3: Association of cortisol measures (per SD) and cardiac remodelling categories

	N	CAR (↑ better)		Slope (↑ worse)		AUC (↑ worse)	
		OR (95%-CI)	P value	OR (95%-CI)	P value	OR (95%-CI)	P value
<i>Remodelling categories</i>							
normal	380	Ref. (1.00)		Ref. (1.00)		Ref. (1.00)	
concentric hypertrophy	143	1.02 (0.84, 1.23)	0.87	0.97 (0.80, 1.19)	0.79	0.93 (0.75, 1.14)	0.47
eccentric hypertrophy	128	0.86 (0.70, 1.05)	0.15	1.00 (0.81, 1.23)	0.99	1.06 (0.88, 1.27)	0.54
concentric remodelling	225	0.88 (0.75, 1.05)	0.15	0.83 (0.70, 0.99)	0.03	0.87 (0.72, 1.05)	0.14

Adjusted for adjusted for sex, waking time, eating or drinking prior to cortisol measurement, education and leisure time physical activity. P for sex interactions were all >0.3.

Abbreviations: AUC, area under the curve from the ground; CAR, cortisol awakening response.

Figure 1: Risk of all-cause, cardiovascular (CV), and non-cardiovascular (NCV) mortality per SD higher cortisol-awakening response (CAR), cortisol slope and area under the curve (AUC) at age 60 to 64 years

